Compare Stocks: DWTX, ACOG, ZNTL, and ANTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACOG Alpha Cognition	$9.04	$9.01	$4.50 ▼ $10.14	$196.89M	2.32	107,698 shs	20,347 shs
ANTX Anthem	$4.40	$5.52	$1.00 ▼ $7.19	$166.06M	-0.98	306,377 shs	442,134 shs
DWTX Dogwood Therapeutics	$1.40	$1.91	$1.28 ▼ $7.04	$47.59M	1.92	68,987 shs	66,325 shs
ZNTL Zentalis Pharmaceuticals	$2.64	$3.54	$1.21 ▼ $6.95	$189.21M	1.93	1.40 million shs	612,359 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACOG Alpha Cognition	0.00%	-0.66%	+1.57%	+7.88%	+28.77%
ANTX Anthem	0.00%	-22.94%	-18.67%	-3.30%	+246.46%
DWTX Dogwood Therapeutics	0.00%	-4.11%	-27.84%	+1.45%	-73.93%
ZNTL Zentalis Pharmaceuticals	0.00%	+4.76%	-24.79%	-42.86%	+57.14%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACOG Alpha Cognition	$9.04	$9.01	$4.50 ▼ $10.14	$196.89M	2.32	107,698 shs	20,347 shs
ANTX Anthem	$4.40	$5.52	$1.00 ▼ $7.19	$166.06M	-0.98	306,377 shs	442,134 shs
DWTX Dogwood Therapeutics	$1.40	$1.91	$1.28 ▼ $7.04	$47.59M	1.92	68,987 shs	66,325 shs
ZNTL Zentalis Pharmaceuticals	$2.64	$3.54	$1.21 ▼ $6.95	$189.21M	1.93	1.40 million shs	612,359 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACOG Alpha Cognition	0.00%	-0.66%	+1.57%	+7.88%	+28.77%
ANTX Anthem	0.00%	-22.94%	-18.67%	-3.30%	+246.46%
DWTX Dogwood Therapeutics	0.00%	-4.11%	-27.84%	+1.45%	-73.93%
ZNTL Zentalis Pharmaceuticals	0.00%	+4.76%	-24.79%	-42.86%	+57.14%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACOG Alpha Cognition	3.00	Buy	$18.00	99.12% Upside
ANTX Anthem	2.33	Hold	$9.00	104.55% Upside
DWTX Dogwood Therapeutics	2.00	Hold	$12.00	757.14% Upside
ZNTL Zentalis Pharmaceuticals	2.50	Moderate Buy	$7.50	184.09% Upside

Current Analyst Ratings Breakdown

Latest DWTX, ACOG, ZNTL, and ANTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/5/2026	ZNTL Zentalis Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform ➝ Outperform	$4.00 ➝ $8.00
10/2/2026	ANTX Anthem	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
10/2/2026	ZNTL Zentalis Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/30/2026	ZNTL Zentalis Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Equal Weight	$5.00
9/16/2026	ZNTL Zentalis Pharmaceuticals	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
9/2/2026	DWTX Dogwood Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/20/2026	ACOG Alpha Cognition	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$21.00
8/17/2026	ACOG Alpha Cognition	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$18.00 ➝ $20.00
8/14/2026	ACOG Alpha Cognition	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$17.00
7/24/2026	DWTX Dogwood Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/23/2026	ZNTL Zentalis Pharmaceuticals	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$11.00

(Data available from 10/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACOG Alpha Cognition	$10.22M	19.27	N/A	N/A	$2.88 per share	3.14
ANTX Anthem	N/A	N/A	N/A	N/A	$1.94 per share	N/A
DWTX Dogwood Therapeutics	N/A	N/A	N/A	N/A	$2.33 per share	N/A
ZNTL Zentalis Pharmaceuticals	$67.43M	2.81	N/A	N/A	$2.99 per share	0.88

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACOG Alpha Cognition	-$20.67M	-$1.10	N/A	N/A	N/A	-153.61%	-54.60%	-43.47%	11/12/2026 (Estimated)
ANTX Anthem	-$35.17M	-$1.07	N/A	N/A	N/A	N/A	-53.52%	-48.63%	N/A
DWTX Dogwood Therapeutics	-$34.26M	-$8.95	N/A	N/A	N/A	N/A	-75.55%	-40.28%	11/5/2026 (Estimated)
ZNTL Zentalis Pharmaceuticals	-$137.06M	-$1.95	N/A	N/A	N/A	N/A	-70.18%	-51.46%	11/10/2026 (Estimated)

Latest DWTX, ACOG, ZNTL, and ANTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	DWTX Dogwood Therapeutics	-$0.15	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q2 2026	ACOG Alpha Cognition	-$0.3921	-$0.40	-$0.0079	-$0.40	$4.38 million	$6.00 million
8/13/2026	Q2 2026	DWTX Dogwood Therapeutics	-$0.14	-$0.34	-$0.20	-$0.34	N/A	N/A
8/11/2026	Q2 2026	ANTX Anthem	N/A	-$0.18	N/A	-$0.18	N/A	N/A
8/6/2026	Q2 2026	ZNTL Zentalis Pharmaceuticals	-$0.49	-$0.59	-$0.10	-$0.59	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACOG Alpha Cognition	N/A	N/A	N/A	N/A	N/A
ANTX Anthem	N/A	N/A	N/A	N/A	N/A
DWTX Dogwood Therapeutics	N/A	N/A	N/A	N/A	N/A
ZNTL Zentalis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACOG Alpha Cognition	N/A	9.03	8.04
ANTX Anthem	N/A	14.32	14.32
DWTX Dogwood Therapeutics	N/A	3.89	3.89
ZNTL Zentalis Pharmaceuticals	N/A	4.82	4.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACOG Alpha Cognition	N/A
ANTX Anthem	90.47%
DWTX Dogwood Therapeutics	9.05%
ZNTL Zentalis Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ACOG Alpha Cognition	8.60%
ANTX Anthem	22.61%
DWTX Dogwood Therapeutics	0.30%
ZNTL Zentalis Pharmaceuticals	3.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACOG Alpha Cognition	71	21.78 million	19.91 million	N/A
ANTX Anthem	N/A	37.74 million	29.20 million	Not Optionable
DWTX Dogwood Therapeutics	8	33.99 million	33.89 million	N/A
ZNTL Zentalis Pharmaceuticals	106	71.67 million	68.95 million	Optionable

DWTX, ACOG, ZNTL, and ANTX Headlines

Recent News About These Companies

Zentalis Pharmaceuticals stock gains 10.32 percent after Leerink upgrade

October 6, 2026 | ad-hoc-news.deA

Zentalis Pharmaceuticals Shares Rise After Leerink Upgrade

October 6, 2026 | finance.yahoo.com

Zentalis Pharmaceuticals stock heads toward October cancer data

October 5, 2026 | ad-hoc-news.deA

Leerink Upgrades Zentalis Pharmaceuticals to Outperform From Market Perform, Price Target is $8

October 5, 2026 | finance.yahoo.com

Zentalis Pharmaceuticals (ZNTL) Gets a Hold from Wells Fargo

October 5, 2026 | theglobeandmail.com

Zentalis Pharmaceuticals Shares Rise After Leerink Assumes Coverage With Outperform Rating

October 5, 2026 | finance.yahoo.com

Leerink Partners Reaffirms Outperform Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL)

October 5, 2026 | americanbankingnews.com

Zentalis Pharmaceuticals' (ZNTL) "Outperform" Rating Reiterated at Leerink Partners

October 5, 2026 | marketbeat.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Rating of "Hold" from Brokerages

October 5, 2026 | americanbankingnews.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Recommendation of "Hold" from Analysts

October 5, 2026 | marketbeat.com

Wells Fargo sets USD 5.00 target for Zentalis Pharmaceuticals stock

October 2, 2026 | ad-hoc-news.deA

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock Picked Up by Analysts at Wells Fargo & Company

October 2, 2026 | americanbankingnews.com

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 1, 2026 | globenewswire.com

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Coverage Initiated by Analysts at Wells Fargo & Company

September 30, 2026 | marketbeat.com

Zentalis Pharmaceuticals, Inc. $ZNTL Shares Newly Acquired by Bank of America Corp DE

September 29, 2026 | marketbeat.com

Zentalis Pharmaceuticals stock falls after public offering pricing and trades below recent highs

September 18, 2026 | ad-hoc-news.deA

William Blair Initiates Coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL)

September 16, 2026 | marketbeat.com

William Blair Starts Zentalis Pharmaceuticals (ZNTL) at Outperform

September 16, 2026 | streetinsider.com

Zentalis Pharmaceuticals, Inc. (ZNTL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 14, 2026 | seekingalpha.com

Zentalis to present at Wells Fargo, Morgan Stanley events

September 2, 2026 | msn.com

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

September 2, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DWTX, ACOG, ZNTL, and ANTX Company Descriptions

Alpha Cognition NASDAQ:ACOG

$9.04 0.00 (0.00%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$9.00 -0.04 (-0.44%)

As of 10/9/2026 07:30 PM Eastern

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.

Anthem NASDAQ:ANTX

$4.40 0.00 (0.00%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$4.41 +0.01 (+0.23%)

As of 05:14 AM Eastern

Anthem, Inc., through its subsidiaries, operates as a health benefits company in the United States. It operates through three segments: Commercial & Specialty Business, Government Business, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small group, individual, Medicaid, and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans; traditional indemnity plans and other hybrid plans, such as consumer-driven health plans; and hospital only and limited benefit products. The company also provides a range of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs, and other administrative services. In addition, it offers an array of specialty and other insurance products and services, such as dental, vision, life and disability insurance benefits, radiology benefit management, and analytics-driven personal health care guidance; and Medicare administrative services. Further, the company provides services to the federal government in connection with the Federal Employee Program; and operates as a licensee of the Blue Cross and Blue Shield Association. As of December 31, 2017, it served 40.2 million medical members through its affiliated health plans. The company was formerly known as WellPoint, Inc. and changed its name to Anthem, Inc. in December 2014. Anthem, Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.

Dogwood Therapeutics NASDAQ:DWTX

$1.40 0.00 (0.00%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.47 +0.07 (+5.00%)

As of 06:03 AM Eastern

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

Zentalis Pharmaceuticals NASDAQ:ZNTL

$2.64 0.00 (0.00%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$2.63 -0.01 (-0.38%)

As of 06:05 AM Eastern

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DWTX, ACOG, ZNTL, and ANTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DWTX, ACOG, ZNTL, and ANTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DWTX, ACOG, ZNTL, and ANTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DWTX, ACOG, ZNTL, and ANTX Company Descriptions

Alpha Cognition NASDAQ:ACOG

Anthem NASDAQ:ANTX

Dogwood Therapeutics NASDAQ:DWTX

Zentalis Pharmaceuticals NASDAQ:ZNTL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DWTX, ACOG, ZNTL, and ANTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DWTX, ACOG, ZNTL, and ANTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DWTX, ACOG, ZNTL, and ANTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DWTX, ACOG, ZNTL, and ANTX Company Descriptions

Alpha Cognition NASDAQ:ACOG

Anthem NASDAQ:ANTX

Dogwood Therapeutics NASDAQ:DWTX

Zentalis Pharmaceuticals NASDAQ:ZNTL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools